TY - JOUR
T1 - Guidelines for mitochondrial RNA analysis
AU - AtheroNET COST Action CA21153
AU - Jusic, Amela
AU - Erpapazoglou, Zoi
AU - Dalgaard, Louise Torp
AU - Lakkisto, Päivi
AU - de Gonzalo-Calvo, David
AU - Benczik, Bettina
AU - Ágg, Bence
AU - Ferdinandy, Péter
AU - Fiedorowicz, Katarzyna
AU - Schroen, Blanche
AU - Lazou, Antigone
AU - Devaux, Yvan
N1 - Funding Information:
This article is based upon work from COST Action EU-CardioRNA CA17129 ( www.cardiorna.eu ), and COST Action AtheroNET, CA21153 ( www.atheronet.eu) .
PY - 2024/9/10
Y1 - 2024/9/10
N2 - Mitochondria are the energy-producing organelles of mammalian cells with critical involvement in metabolism and signaling. Studying their regulation in pathological conditions may lead to the discovery of novel drugs to treat, for instance, cardiovascular or neurological diseases, which affect high-energy-consuming cells such as cardiomyocytes, hepatocytes, or neurons. Mitochondria possess both protein-coding and noncoding RNAs, such as microRNAs, long noncoding RNAs, circular RNAs, and piwi-interacting RNAs, encoded by the mitochondria or the nuclear genome. Mitochondrial RNAs are involved in anterograde-retrograde communication between the nucleus and mitochondria and play an important role in physiological and pathological conditions. Despite accumulating evidence on the presence and biogenesis of mitochondrial RNAs, their study continues to pose significant challenges. Currently, there are no standardized protocols and guidelines to conduct deep functional characterization and expression profiling of mitochondrial RNAs. To overcome major obstacles in this emerging field, the EU-CardioRNA and AtheroNET COST Action networks summarize currently available techniques and emphasize critical points that may constitute sources of variability and explain discrepancies between published results. Standardized methods and adherence to guidelines to quantify and study mitochondrial RNAs in normal and disease states will improve research outputs, their reproducibility, and translation potential to clinical application.
AB - Mitochondria are the energy-producing organelles of mammalian cells with critical involvement in metabolism and signaling. Studying their regulation in pathological conditions may lead to the discovery of novel drugs to treat, for instance, cardiovascular or neurological diseases, which affect high-energy-consuming cells such as cardiomyocytes, hepatocytes, or neurons. Mitochondria possess both protein-coding and noncoding RNAs, such as microRNAs, long noncoding RNAs, circular RNAs, and piwi-interacting RNAs, encoded by the mitochondria or the nuclear genome. Mitochondrial RNAs are involved in anterograde-retrograde communication between the nucleus and mitochondria and play an important role in physiological and pathological conditions. Despite accumulating evidence on the presence and biogenesis of mitochondrial RNAs, their study continues to pose significant challenges. Currently, there are no standardized protocols and guidelines to conduct deep functional characterization and expression profiling of mitochondrial RNAs. To overcome major obstacles in this emerging field, the EU-CardioRNA and AtheroNET COST Action networks summarize currently available techniques and emphasize critical points that may constitute sources of variability and explain discrepancies between published results. Standardized methods and adherence to guidelines to quantify and study mitochondrial RNAs in normal and disease states will improve research outputs, their reproducibility, and translation potential to clinical application.
KW - gene expression
KW - guidelines
KW - microRNAs
KW - mitochondria
KW - MT: Non-coding RNAs
KW - noncoding RNAs
KW - gene expression
KW - guidelines
KW - microRNAs
KW - mitochondria
KW - MT: Non-coding RNAs
KW - noncoding RNAs
U2 - 10.1016/j.omtn.2024.102262
DO - 10.1016/j.omtn.2024.102262
M3 - Review
AN - SCOPUS:85198012146
SN - 2162-2531
VL - 35
JO - Molecular Therapy Nucleic Acids
JF - Molecular Therapy Nucleic Acids
IS - 3
M1 - 102262
ER -